Antimicrobial delivery systems for local infection prophylaxis in orthopedic- and trauma surgery

Biomaterials

Volumn 52, Issue 1, 2015, Pages 113-125

  ter Boo, Gert Jan A ^a,b   Grijpma, Dirk W ^b,c   Moriarty, Thomas F ^a   Richards, Robert G ^a   Eglin, David ^a  

^a AO RESEARCH INSTITUTE   (Switzerland)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antimicrobial; Biofilm; Controlled release; Medical device associated infection; Prophylaxis; Responsive materials

Indexed keywords

ANTIBIOTICS; BIOFILMS; FRACTURE FIXATION; HEALTH RISKS; JOINT PROSTHESES; MICROORGANISMS; PHYSIOLOGICAL MODELS; POLYMERS; SURGERY;

ANTIMICROBIAL; CONTROLLED RELEASE; MEDICAL DEVICES; PROPHYLAXIS; RESPONSIVE MATERIALS;

POLYMERIC IMPLANTS;

ANTIINFECTIVE AGENT; DRUG CARRIER; POLYPEPTIDE ANTIBIOTIC AGENT; SILVER; DELAYED RELEASE FORMULATION; POLYMER;

ANTIBIOTIC RESISTANCE; ARTHROPLASTY; BIOFILM; BONE IMPLANT; CELL VIABILITY; CYTOTOXICITY; DEGRADATION; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; FRACTURE FIXATION; HEALTH STATUS; HUMAN; IN VITRO STUDY; INFECTION PREVENTION; JOINT SURGERY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; TRAUMATOLOGY; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DEVICES; PROCEDURES; SURGICAL WOUND INFECTION;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTI-INFECTIVE AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; POLYMERS; SURGICAL WOUND INFECTION;

EID: 84932650742     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.020     Document Type: Review

References (140)

1. National Center for Biotechnology I Infection 2012.
2. Scottish Intercollegiate Guidelines N Antibiotic prophylaxis in surgery. A national clinical guideline 2008.
3. Greene L.R. Guide to the elimination of orthopedic surgery surgical site infections: an executive summary of the Association for Professionals in Infection Control and Epidemiology elimination guide. Am J Infect Control 2012, 40:384-386.
4. Elek S.D., Conen P.E. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol 1957, 38:573-586.
5. Zimmerli W., Waldvogel F.A., Vaudaux P., Nydegger U.E. Pathogenesis of foreign body infection: description and characteristics of an animal model. JInfect Dis 1982, 146:487-497.
6. Busscher H.J., van der Mei H.C., Subbiahdoss G., Jutte P.C., van den Dungen J.J., Zaat S.A., et al. Biomaterial-associated infection: locating the finish line in the race for the surface. SciTranslMed 2012, 4:153rv10.
7. Rochford E.T., Richards R.G., Moriarty T.F. Influence of material on the development of device-associated infections. Clin Microbiol Infect 2012, 18:1162-1167.
8. Trampuz A., Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006, 37:S59-S66.
9. Trampuz A., Widmer A.F. Infections associated with orthopedic implants. Curr Opin Infect Dis 2006, 19:349-356.
10. Diefenbeck M., Muckley T., Hofmann G.O. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury 2006, 37(Suppl.2):S95-S104.
11. Schmidmaier G., Lucke M., Wildemann B., Haas N.P., Raschke M. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury 2006, 37:S105-S112.
12. Weinstein R.A., Darouiche R.O. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis 2001, 33:1567-1572.
13. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999, 27:97-132.
14. Zimmerli W. Antibiotic prophylaxis. AO principles of fracture management 2007, 425-433. AO Publishing, Davos Platz. T.P. Rüedi, R.E. Buckley, C.G. Moran (Eds.).
15. Del Pozo J.L., Patel R. Infection associated with prosthetic joints. NEngl J Med 2009, 361:787-794.
16. Boxma H., Broekhuizen T., Patka P., Oosting H. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch Trauma Trial. Lancet 1996, 347:1133-1137.
17. Esposito S., Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int J Antimicrob Agents 2008, 32:287-293.
18. Glenny A., Song F. Antimicrobial prophylaxis in total hip replacement: a systematic review. Health Technol Assess 1999, 3:1-57.
19. Tamilvanan S., Venkateshan N., Ludwig A. The potential of lipid- and polymer-based drug delivery carriers for eradicating biofilm consortia on device-related nosocomial infections. JControl Release 2008, 128:2-22.
20. Aarestrup F.M. Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals. Int J Antimicrob Agents 1999, 12:279-285.
21. Kardas P., Devine S., Golembesky A., Roberts C. Asystematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 2005, 26:106-113.
22. Tunney M.M., Patrick S., Gorman S.P., Nixon J.R., Anderson N., Davis R.I., et al. Improved detection of infection in hip replacements. JBone Jt Surg Br Volume 1998, 80-B:568-572.
23. Norden C.W. Osteomyelitis. Principles and practice of infectious diseases 1990, 922-930. Churchill Livingstone, New York. G.L. Mandell, R.G. Douglas, J.E. Bennett (Eds.).
24. Ochsner P.E., Sirkin M.S., Trampuz A. Acute infection. AO principles of fracture management 2007, 521-541. AO Publishing, Davos Platz. T.P. Rüedi, R.E. Buckley, C.G. Moran (Eds.).
25. Johnson E.E., Buckley R.E. Chronic infection and infected nonunion. AO principles of fracture management 2007, 543-555. AO Publishing, Davos Platz. T.P. Rüedi, R.E. Buckley, C.G. Moran (Eds.).
26. Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res 2005, 437:41-47.
27. Mack D., Fischer W., Krokotsch A., Leopold K., Hartmann R., Egge H., et al. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. JBacteriol 1996, 178:175-183.
28. Flemming H.-C., Wingender J. The biofilm matrix. Nat Rev Micro 2010, 8:623-633.
29. Montanaro L., Poggi A., Visai L., Ravaioli S., Campoccia D., Speziale P., et al. Extracellular DNA in biofilms. Int J Artif Organs 2011, 34:824-831.
30. National Center for Biotechnology I Biofilm 2013.
31. Donlan R.M. Biofilms and device-associated infections. Emerg Infect Dis 2001, 7:277-281.
32. Donlan R.M. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002, 8:881-890.
33. Anderl J.N., Franklin M.J., Stewart P.S. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother 2000, 44:1818-1824.
34. Costerton J.W. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005, 7-11.
35. von Eiff C., Heilmann C., Peters G. Staphylococcus epidermidis: why is it so successful?. Clin Microbiol Infect 1998, 4:297-300.
36. Peng K.T., Chen C.F., Chu I.M., Li Y.M., Hsu W.H., Hsu R.W.W., et al. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials 2010, 31:5227-5236.
37. Darouichi R.O. Treatment of infections associated with surgical implants. N.Engl J Med 2004, 350:1422-1429.
38. Rubin R.J., Harrington C.A., Poon A., Dietrich K., Greene J.A., Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999, 5:9-17.
39. National Center for Biotechnology I Antibiotic prophylaxis 2012.
40. Kaiser A.B. Antimicrobial prophylaxis in surgery. NEngl J Med 1986, 315:1129-1138.
41. Haas D.W., Kaiser A.B. Antimicrobial prophylaxis of infections associated with foreign bodies. Infections associated with indwelling medical devices 2000, 395-406. John Wiley & Sons, Washington DC. F.A. Waldvogel, A.L. Bisno (Eds.).
42. Jaeger M., Maier D., Kern W.V., Südkamp N.P. Antibiotics in trauma and orthopedic surgery - a primer of evidence-based recommendations. Injury 2006, 37:S74-S80.
43. Gustilo R.B., Merkow R.L., Templeman D. The management of open fractures. JBone Jt Surg Am 1990, 72:299-304.
44. Classen D.C., Evans R.S., Pestotnik S.L., Horn S.D., Menlove R.L., Burke J.P. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. NEngl J Med 1992, 326:281-286.
45. Ito K., Perren S.M. Biology and biomechanics in bone healing. AO principles of fracture management 2007, 9-31. AO Publishing, Davos Platz. T.P. Rüedi, R.E. Buckley, C.G. Moran (Eds.).
46. Deguchi T., Ishi A., Tanaka M. Binding of aminoglycoside antibiotics to acidic mucopolysaccharides. JAntibiot(Tokyo) 1978, 31:150-155.
47. Mingeot-Leclercq M.P., Tulkens P.M. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999, 43:1003-1012.
48. Naughton C.A. Drug-induced nephrotoxicity. Am Fam Physician 2008, 78:743-750.
49. Elyasi S., Khalili H., Dashti-Khavidaki S., Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012, 68:1243-1255.
50. Kubin C.J., Ellman T.M., Phadke V., Haynes L.J., Calfee D.P., Yin M.T. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. JInfect 2012, 65:80-87.
51. Durante-Mangoni E., Grammatikos A., Utili R., Falagas M.E. Do we still need the aminoglycosides?. Int J Antimicrob Agents 2009, 33:201-205.
52. Begg E.J., Barclay M.L. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995, 39:597-603.
53. Griffis C.D., Metcalfe S., Bowling F.L., Boulton A.J.M., Armstrong D.G. The use of gentamicin-impregnated foam in the management of diabetic foot infections: a promising delivery system?. Expert Opin Drug Deliv 2009, 6:639-642.
54. Raschke M.J., Schmidmaier G. Biologisierung von Implantaten in der Chirurgie des Stütz- und Bewegungsapparates. Der Unfallchirurg 2004, 107:653-663.
55. Barth R.E., Vogely H.C., Hoepelman A.I., Peters E.J. 'To bead or not to bead?' Treatment of osteomyelitis and prosthetic joint-associated infections with gentamicin bead chains. Int J AntimicrobAgents 2011, 38:371-375.
56. Baudoux P., Bles N., Lemaire S., Mingeot-Leclercq M.-P., Tulkens P.M., Van Bambeke F. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. JAntimicrob Chemother 2007, 59:246-253.
57. Schlessinger D. Failure of aminoglycoside antibiotics to kill anaerobic, low-pH, and resistant cultures. Clin Microbiol Rev 1988, 1:54-59.
58. Madigan M.T., Martinko J.M., Parker J. Microbial growth control. Brock; biology of microorganisms 2000.
59. Berger-Bächi B., McCallum N. State of the knowledge of bacterial resistance. Injury 2006, 37:S20-S25.
60. Lee S.H., Lee J.E., Baek W.Y., Lim J.O. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media invitro and invivo. JControl Release 2004, 96:1-7.
61. Hajdu S., Lassnigg A., Graninger W., Hirschl A.M., Presterl E. Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. JOrthop Res 2009, 1361-1365.
62. Winkler H., Janata O., Berger C., Wein W., Georgopoulos A. Invitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts. JAntimicrob Chemother 2000, 46:423-428.
63. Rathbone C.R., Cross J.D., Brown K.V., Murray C.K., Wenke J.C. Effect of various concentrations of antibiotics on osteogenic cell viability and activity. JOrthop Res 2011, 29:1070-1074.
64. Isefuku S., Joyner C.J., Simpson A.H. Gentamicin may have an adverse effect on osteogenesis. JOrthop Trauma 2003, 17:212-216.
65. Halleem A.A., Rouse M.S., Lewallen D.G., Hanssen A.D., Steckelberg J.M., Patel R. Gentamicin and vancomycin do not impair experimental fracture healing. Clin Orthop Relat Res 2004, 427:22-24.
66. McLaren A.C. Alternative materials to acrylic bone cement for delivery of depot antibiotics in orthopaedic infections. Clin Orthop Relat Res 2004, 427:101-106.
67. Tunney M.M., Ramage G., Patrick S., Nixon J.R., Murphy P.G., Gorman S.P. Antimicrobial susceptibility of bacteria isolated from orthopedic implants following revision hip surgery. Antimicrob Agents Chemother 1998, 42:3002-3005.
68. Buchholz H.W., Engelbrecht H. Depot effects of various antibiotics mixed with Palacos resins. Chirurg 1970, 41:511-515.
69. Kuehn K.D., Ege W., Gopp U. Acrylic bone cements: composition and properties. Orthop ClinNorth Am 2005, 36:17-28. v.
70. Serbetci K., Hasirci N. Recent developments in bone cements. Biomaterials in orthopedics 2004, 241-286.
71. Lewis G., Janna S. The invitro elution of gentamicin sulfate from a commercially available gentamicin-loaded acrylic bone cement, VersaBond AB. JBiomed Mater Res B Appl Biomater 2004, 71:77-83.
72. Frutos C.P., Diez P.E., Barrales-Rienda J.M., Frutos G. Validation and invitro characterization of antibiotic-loaded bone cement release. Int J Pharm 2000, 209:15-26.
73. Engesaeter L.B., Lie S.A., Espehaug B., Furnes O., Vollset S.E., Havelin L.I. Antibiotic prophylaxis in total hip arthroplasty effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop 2003, 74:644-651.
74. Weber F.A., Lautenbach E.E.G. Revision of infected total hip arthroplasty. Clin Orthop Relat Res 1986, 108-115.
75. Hope P.G., Kristinsson K.G., Norman P., Elson R.A. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. JBone Jt Surg Br 1989, 71:851-855.
76. Yoshii E. Cytotoxic effects of acrylates and methacrylates: relationships of monomer structures and cytotoxicity. JBiomed Mater Res 1997, 37:517-524.
77. Kilian O., Hossain H., Flesch I., Sommer U., Nolting H., Chakraborty T., et al. Elution kinetics, antimicrobial efficacy, and degradation and microvasculature of a new gentamicin-loaded collagen fleece. JBiomed Mater Res B Appl Biomater 2009, 90:210-222.
78. Ruszczak Z., Friess W. Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev 2003, 55:1679-1698.
79. Sorensen T.S., Sorensen A.I., Merser S. Rapid release of gentamicin from collagen sponge. Invitro comparison with plastic beads. Acta Orthop Scand 1990, 61:353-356.
80. El-Husseiny M., Patel S., MacFarlane R.J., Haddad F.S. Biodegradable antibiotic delivery systems. JBone Jt Surg Br Volume 2011, 93-B:151-157.
81. Schlapp M., Friess W. Collagen/PLGA microparticle composites for local controlled delivery of gentamicin. JPharm Sci 2003, 92:2145-2151.
82. Campoccia D., Montanaro L., Speziale P., Arciola C.R. Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials 2010, 31:6363-6377.
83. Imbuluzqueta E., Elizondo E., Gamazo C., Moreno-Calvo E., Veciana J., Ventosa N., et al. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections. Acta Biomater 2011, 7:1599-1608.
84. Meyer J.D., Falk R.F., Kelly R.M., Shively J.E., Withrow S.J., Dernell W.S., et al. Preparation and invitro characterization of gentamycin-impregnated biodegradable beads suitable for treatment of osteomyelitis. JPharm Sci 1998, 87:1149-1154.
85. Obermeier A., Matl F.D., Schwabe J., Zimmermann A., Kuhn K.D., Lakemeier S., et al. Novel fatty acid gentamicin salts as slow-release drug carrier systems for anti-infective protection of vascular biomaterials. JMater Sci Mater Med 2012, 23:1675-1683.
86. Schnieders J., Gbureck U., Thull R., Kissel T. Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement. Biomaterials 2006, 27:4239-4249.
87. Vogt S., Kühn K.D., Gopp U., Schnabelrauch M. Resorbable antibiotic coatings for bone substitutes and implantable devices. Materialwissenschaft und Werkstofftechnik 2005, 36:814-819.
88. Holzer B., Grüssner U., Brückner B., Houf M., Kiffner E., Schildberg F.W., et al. Efficacy and tolerance of a new gentamicin collagen fleece (Septocoll) after surgical treatment of a pilonidal sinus. Colorectal Dis 2003, 5:222-227.
89. Friess W. Collagen-biomaterial for drug delivery. Eur J Pharm Biopharm 1998, 45:113-136.
90. Fuchs T., Stange R., Schmidmaier G., Raschke M.J. The use of gentamicin-coated nails in the tibia: preliminary results of a prospective study. Arch Orthop Trauma Surg 2011, 131:1419-1425.
91. Gunatillake P.A., Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003, 5:1-16.
92. Bostman O.M. Osteolytic changes accompanying degradation of absorbable fracture fixation implants. JBone Jt Surg Br Volume 1991, 73-B:679-682.
93. Heidemann W., Jeschkeit-Schubbert S., Ruffieux K., Fischer J.H., Jung H., Krueger G., et al. pH-stabilization of predegraded PDLLA by an admixture of water-soluble sodiumhydrogenphosphate-results of an invitro- and invivo-study. Biomaterials 2002, 23:3567-3574.
94. Sung H.-J., Meredith C., Johnson C., Galis Z.S. The effect of scaffold degradation rate on three-dimensional cell growth and angiogenesis. Biomaterials 2004, 25:5735-5742.
95. Wu L., Ding J. Invitro degradation of three-dimensional porous poly(d,l-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 2004, 25:5821-5830.
96. Agrawal C.M., Athanasiou K.A. Technique to control pH in vicinity of biodegrading PLA-PGA implants. JBiomed Mater Res 1997, 38:105-114.
97. Marcus Y., Sasson K., Fridkin M., Shechter Y. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin. JMed Chem 2008, 51:4300-4305.
98. Coessens V., Schacht E., Domurado D. Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. JControl Release 1996, 38:141-150.
99. Choi S.K., Myc A., Silpe J.E., Sumit M., Wong P.T., McCarthy K., et al. Dendrimer-based multivalent vancomycin nanoplatform for targeting the drug-resistant bacterial surface. ACS Nano 2013, 7:214-228.
100. Rai M., Yadav A., Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27:76-83.
101. Poulter N., Vasilev K., Griesser S.S., Griesser H.J. Silver containing biomaterials. Biomaterials associated infection 2013, 355-378. Springer, New York. T.F. Moriarty, S.A.J. Zaat, H.J. Busscher (Eds.).
102. Hetrick E.M., Schoenfisch M.H. Reducing implant-related infections: active release strategies. Chem Soc Rev 2006, 35:780-789.
103. Alt V., Bechert T., Steinrücke P., Wagener M., Seidel P., Dingeldein E., et al. An invitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. Biomaterials 2004, 25:4383-4391.
104. Montali A. Antibacterial coating systems. Injury 2006, 37:S81-S86.
105. Pal S., Tak Y.K., Song J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-Negative Bacterium Escherichia coli. Appl Environ Microbiol 2007, 73:1712-1720.
106. Travan A., Pelillo C., Donati I., Marsich E., Benincasa M., Scarpa T., et al. Non-cytotoxic silver nanoparticle-polysaccharide nanocomposites with antimicrobial activity. Biomacromolecules 2009, 10:1429-1435.
107. Guo L., Yuan W., Lu Z., Li C.M. Polymer/nanosilver composite coatings for antibacterial applications. Colloids Surfaces A: Physicochem Eng Asp 2013, 439:69-83.
108. Pelgrift R.Y., Friedman A.J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 2013, 65:1803-1815.
109. Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 2003, 27:341-353.
110. Jenssen H., Hamill P., Hancock R.E. Peptide antimicrobial agents. Clin Microbiol Rev 2006, 19:491-511.
111. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
112. Epand R.M., Vogel H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999, 1462:11-28.
113. Yeung A.Y., Gellatly S., Hancock R.W. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 2011, 68:2161-2176.
114. Kang S.-J., Park S.J., Mishig-Ochir T., Lee B.-J. Antimicrobial peptides: therapeutic potentials. Expert Rev Anti-infective Ther 2014, 12:1477-1486.
115. Costa F., Carvalho I.F., Montelaro R.C., Gomes P., Martins M.C. Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater 2011, 7:1431-1440.
116. Daghighi S., Sjollema J., van der Mei H.C., Busscher H.J., Rochford E.T.J. Infection resistance of degradable versus non-degradable biomaterials: an assessment of the potential mechanisms. Biomaterials 2013, 34:8013-8017.
117. Andreopoulos A.G., Hatzi E.C., Doxastakis M. Controlled release systems based on poly(lactic acid). An invitro and invivo study. JMater Sci Mater Med 2000, 11:393-397.
118. Kanellakopoulou K., Galanakis N., Giamarellos-Bourboulis E.J., Rifiotis C., Papakostas K., Andreopoulos A., et al. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. JAntimicrob Chemother 2000, 46:311-314.
119. Koort J.K., Makinen T.J., Suokas E., Veiranto M., Jalava J., Tormala P., et al. Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant. Acta Orthop 2008, 79:295-301.
120. Mauduit J., Bukh N., Vert M. Gentamycin/poly (lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. III. The case of gentamycin sulfate in films prepared from high and low molecular weight poly (DL-lactic acids). JControl Release 1993, 25:43-49.
121. Mauduit J., Bukh N., Vert M. Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. II. The case of gentamycin sulfate in high molecular weight poly(dl-lactic acid) and poly(l-lactic acid). JControl Release 1993, 23:221-230.
122. Mauduit J., Bukh N., Vert M. Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. I. The case of gentamycin base and gentamycin sulfate in poly(dl-lactic acid) oligomers. JControl Release 1993, 23:209-220.
123. Suzuki A., Terai H., Toyoda H., Namikawa T., Yokota Y., Tsunoda T., et al. Abiodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. JOrthop Res 2006, 24:327-332.
124. Vogt S., Kühn K.D., Ege W., Pawlik K., Schnabelrauch M. Novel polylactide-based release systems for local antibiotic therapies. Materialwissenschaft und Werkstofftechnik 2003, 34:1041-1047.
125. Wei G., Kotoura Y., Oka M., Yamamuro T., Wada R., Hyon S.H., et al. Abioabsorbable delivery system for antibiotic treatment of osteomyelitis. The use of lactic acid oligomer as a carrier. JBone Jt Surg Br Volume 1991, 73-B:246-252.
126. Zhang X., Wyss U.P., Pichora D., Goosen M.F.A. Amechanistic study of antibiotic release from biodegradable poly(d,l-lactide) cylinders. JControl Release 1994, 31:129-144.
127. Zhang X.I.C.H., Wyss U.P., Pichora D.A.V.I., Goosen M.F.A. Biodegradable controlled antibiotic release devices for osteomyelitis: optimization of release properties. JPharm Pharmacol 1994, 46:718-724.
128. Garvin K.L., Miyano J.A., Robinson D., Giger D., Novak J., Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. A canine model. JBone Jt Surg Am 1994, 76:1500-1506.
129. Kim K., Luu Y.K., Chang C., Fang D., Hsiao B.S., Chu B., et al. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. JControl Release 2004, 98:47-56.
130. Chang H.I., Perrie Y., Coombes A.G.A. Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone. JControl Release 2006, 110:414-421.
131. Teo E.Y., Ong S.Y., Khoon C., Mark S., Zhang Z., Lu J., et al. Polycaprolactone-based fused deposition modeled mesh for delivery of antibacterial agents to infected wounds. Biomaterials 2011, 32:279-287.
132. Mader J.T., Calhoun J., Cobos J. Invitro evaluation of antibiotic diffusion from antibiotic-impregnated biodegradable beads and polymethylmethacrylate beads. Antimicrob Agents Chemother 1997, 41:415-418.
133. Neut D., Kluin O.S., Crielaard B.J., van der Mei H.C., Busscher H.J., Grijpma D.W. Abiodegradable antibiotic delivery system based on poly(trimethylene carbonate) for the treatment of osteomyelitis. Acta Orthop 2009, 80:514-519.
134. Zhang Z., Kuijer R., Bulstra S.K., Grijpma D.W., Feijen J. The invivo and invitro degradation behavior of poly(trimethylene carbonate). Biomaterials 2006, 27:1741-1748.
135. Pego A.P., Van Luyn M.J., Brouwer L.A., van Wachem P.B., Poot A.A., Grijpma D.W., et al. Invivo behavior of poly(1,3-trimethylene carbonate) and copolymers of 1,3-trimethylene carbonate with d,l-lactide or epsilon-caprolactone: degradation and tissue response. JBiomed Mater Res A 2003, 67:1044-1054.
136. Sripriya R., Kumar M.S., Sehgal P.K. Improved collagen bilayer dressing for the controlled release of drugs. JBiomed Mater Res B Appl Biomater 2004, 70:389-396.
137. Veyries M.L., Couarraze G., Geiger S., Agnely F., Massias L., Kunzli B., et al. Controlled release of vancomycin from Poloxamer 407 gels. Int J Pharm 1999, 192:183-193.
138. Simões S.M.N., Veiga F., Torres-Labandeira J.J., Ribeiro A.C.F., Sandez-Macho M.I., Concheiro A., et al. Syringeable Pluronic-α-cyclodextrin supramolecular gels for sustained delivery of vancomycin. Eur J Pharm Biopharm 2012, 80:103-112.
139. Woo G.L., Mittelman M.W., Santerre J.P. Synthesis and characterization of a novel biodegradable antimicrobial polymer. Biomaterials 2000, 21:1235-1246.
140. Suzuki Y., Tanihara M., Nishimura Y., Suzuki K., Kakimaru Y., Shimizu Y. Anew drug delivery system with controlled release of antibiotic only in the presence of infection. JBiomed Mater Res 1998, 42:112-116.